Bortezomib will improve the level or influence of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Improved flibanserin adverse consequences may possibly take place if coadministered with a number of weak CYP3A4 inhibitors. Acute advancement or exacerbation of congestive heart failure and new onset of lessened https://marjaneyb332pbl5.bligblogging.com/profile